

LIST OF FIGURES

Figure No.	Figure captions	Page No.
1.1	Clinical uses of ceramics, glasses and composites in the human body.	2
1.2	Effect of age on the strength of bone or bone mass in male and female.	5
1.3	Compositional dependence (wt %) of bone bonding and soft tissue bonding of bioactive glasses and glass-ceramics.	10
1.4	Time dependence of reactions occurring on a bioactive implant surface and the effects on cells leading to rapid bone bonding and bone proliferation.	22
1.5	Cell cycle.	25
3.1	Variation in density with $\text{Al}_2\text{O}_3/\text{Li}_2\text{O}$ ratio in bioglass samples LiAl0.0 to LiAl2.5.	54
3.2	Variation in compressive strength with $\text{Al}_2\text{O}_3/\text{Li}_2\text{O}$ ratio in bioglass samples (LiAl0.0 to LiAl2.5).	55
3.3	Elastic modulus, shear modulus and bulk modulus of all bioglass samples (LiAl0.0-LiAl2.5).	56
3.4	Vickers hardness of the bioglass samples (LiAl0.0-LiAl2.5).	58
3.5	Variation of pH of bioactive glass samples (LiAl0.0 to LiAl2.5) after immersing in simulated body fluid (SBF) up to 28 days.	60
3.6	XRD patterns of the bioactive glass samples (LiAl0.0 to LiAl2.5) before soaking them into the simulated body fluid solution.	63
3.7	XRD patterns of the bioactive glass samples (LiAl0.0 to	64

	LiAl2.5) soaked in the simulated body fluid solution for 14 days.	
3.8 (a-e)	SEM micrographs of bioactive glass samples (LiAl0.0 to LiAl2.5) before soaking in SBF solution	65
3.9 (a-e)	SEM micrographs of bioactive glass samples (LiAl0.0 to LiAl2.5) which were soaked in SBF solution for 28 days.	66
3.10	FTIR absorption spectra of all glass samples (a) before soaking them into SBF solution, (b) after soaking them into SBF for 1 day, (c) after soaking them into SBF for 3 day and (d) after soaking them into SBF for 7 days.	68
3.11	Viability of MG63 cells in the presence of fixed concentration (10 mg/ml) of bioactive glass samples (LiAl0.0 to LiAl2.5).	70
3.12	Cytotoxicity of MG63 cells in the presence of fixed concentration (10mg/ml) of bioactive glass samples (LiAl0.0 to LiAl2.5).	71
4.1	Variation in density with Al ₂ O ₃ /K ₂ O ratio in bioactive glass samples (K1-K5).	86
4.2	Variation in compressive strength with Al ₂ O ₃ /K ₂ O ratio in bioactive glass samples (K1-K5).	87
4.3	Elastic modulus, shear modulus and bulk modulus of all bioactive glass samples (K1-K5).	88
4.4	Variation of pH of bioactive glass samples (K1-K5) after immersing in simulated body fluid (SBF) up to 28 days at 37°C temperature.	90
4.5 (a-e)	SEM micrographs of bioactive glass samples (K1-K5) before soaking in SBF solution.	92
4.6 (a-e)	SEM micrographs of bioactive glass samples (K1-K5) which were soaked in SBF solution for 28 days.	93

4.7	XRD patterns of the bioactive glass samples (K1-K5) before soaking them into the simulated body fluid (SBF) solution.	94
4.8	XRD patterns of the bioactive glass samples (K1-K5) soaked in the simulated body fluid (SBF) solution for 28 days.	95
4.9	FTIR absorption spectra of bioactive glass, K1 before and after soaking in SBF solution.	96
4.10	FTIR absorption spectra of bioactive glass, K2 before and after soaking in SBF solution.	97
4.11	FTIR absorption spectra of bioactive glass, K3 before and after soaking in SBF solution.	98
4.12	FTIR absorption spectra of bioactive glass, K4 before and after soaking in SBF solution.	99
4.13	FTIR absorption spectra of bioactive glass, K5 before and after soaking in SBF solution.	100
4.14	Higher concentrations of bioactive glass sample inhibit osteosarcoma cells. (A) XTT Viability of U2-OS cells in presence of fixed concentration (25 mg/ml) of bioactive glass sample. (B) Anti-proliferative effect of increasing concentrations of bioactive glass sample against U2-OS cells assessed by MTT assay. (C) Direct cytotoxicity of U2-OS cells in presence of increasing concentrations of bioactive glass samples. Data presented as Mean \pm SD with triplicate determination, n=3.	102
4.15	Bioactive glass samples are tolerant to human RBC and PBMC. (A) Lack of hemolysis in RBC by bioactive glass samples in time dependent kinetic study. (B) Viability of PBMC was studied by XTT assay in presence varying concentrations of indicated samples. Mean \pm SD, n=3.	103
4.16	Microscopic analysis of induction of apoptosis.	104

4.17	Phagocytosis of bioactive glass sample by human macrophages.	105
4.18 (a-e)	SEM micrographs of U2-OS cells growth on biocompatible glass samples (K1-K5).	107
5.1	Variation in density with Al ₂ O ₃ /SrO ratio in bioactive glass samples Sr-1 to Sr-5.	119
5.2	Variation in compressive strength with Al ₂ O ₃ /SrO ratio in bioactive glass samples Sr-1 to Sr-5.	120
5.3	Elastic modulus, shear modulus and bulk modulus of all bioactive glass samples Sr-1 to Sr-5.	121
5.4	Variation of pH of bioactive glass samples (Sr-1 to Sr-5) after immersing in simulated body fluid (SBF) up to 28 days.	123
5.5	XRD patterns of the bioactive glass samples (Sr-1 to Sr-5) before soaking them into the simulated body fluid (SBF) solution.	125
5.6	XRD patterns of the bioactive glass samples (Sr-1 to Sr-5) soaked in the simulated body fluid (SBF) solution for 14 days.	126
5.7 (a-e)	SEM micrographs of bioactive glass samples (Sr-1 to Sr-5) before soaking in SBF solution.	127
5.8	SEM micrographs of bioactive glass samples (Sr-1 to Sr-5) which were soaked in SBF solution for 28 days.	128
5.9	FTIR absorption spectra of all the glass samples (Sr-1 to Sr-5) before soaking them into SBF solution.	130
5.10	FTIR absorption spectra of all the glass samples (Sr-1 to Sr-5) after soaking them into SBF for 14 days.	131
5.11	(A) XTT Viability of U2-OS cells in the presence of fixed concentration (25 mg/ml) of bioactive glass sample. (B) Anti-proliferative effect of increasing concentrations of bioactive glass sample against U2-OS cells assessed by	133

	MTT assay. (C) Direct cytotoxicity of U2-OS cells in presence of increasing concentrations of bioactive glass samples.	
5.12	(A) Lack of hemolysis in RBC by bioactive glass samples (Sr-1 to Sr-5) in time dependent kinetic study. (B) Viability of PBMC studied by XTT assay in presence varying concentrations of indicated samples.	135
5.13	SEM micrographs of U2-OS cells growth on biocompatible glass samples (Sr-1 to Sr-5).	136
6.1	Variation of compressive strength with composition of the bioactive glass samples (45S5 to Cu-4).	152
6.2	Variation in elastic modulus, shear modulus and bulk modulus of all bioactive glass samples (45S5 to Cu-4) with CuO content.	153
6.3	XRD patterns of the bioactive glass samples (45S5 to Cu-4) before soaking them into the simulated body fluid (SBF) solution.	155
6.4	XRD patterns of the bioactive glass samples (45S5 to Cu-4) soaked in the simulated body fluid (SBF) solution for 14 days.	155
6.5 (a-e)	SEM micrographs of bioactive glass samples (45S5 to Cu-4) before soaking in SBF solution.	157
6.6 (a-e)	SEM micrographs of bioactive glass samples (45S5 to Cu-4) after soaking in SBF solution.	158
6.7	Variation of pH of bioactive glass samples (45S5 to Cu-4) after immersing in SBF up to 28 days.	160
6.8	FTIR absorption spectra of all glass samples (45S5 to Cu-4) before soaking them into SBF solution.	161
6.9	FTIR absorption spectra of all glass samples (45S5 to Cu-4) after soaking them into SBF for 7 days.	162

6.10	Antibacterial effect of bioglass samples 45S5, Cu-1, Cu-2 and Cu-3 towards E. coli suspension for 24 hrs.	164
7.1	Variation of compressive strength with composition of the bioactive glass samples (45S5 to TZ4).	177
7.2	(a) XRD patterns of bioactive glass samples (45S5 to TZ4) before immersing the samples in SBF. (b) XRD patterns of bioactive glass samples (45S5 to TZ4) after immersing the samples in SBF for 14 days.	178
7.3	Variation of pH of the SBF solution containing glass samples (45S5 to TZ4) with different time intervals.	180
7.4	SEM micrographs of bioactive glass samples (45S5 to TZ4) before soaking in SBF solution.	182
7.5	SEM micrographs of bioactive glass samples (45S5 to TZ4) after soaking in SBF solution.	183
7.6	FTIR transmission spectra of 45S5 bioactive glass sample before and after SBF treatment.	184
7.7	FTIR transmission spectra of bioactive glass sample TZ1 before and after SBF treatment.	185
7.8	FTIR transmission spectra of bioactive glass sample TZ2 before and after SBF treatment.	186
7.9	FTIR transmission spectra of bioactive glass sample TZ3 before and after SBF treatment.	187
7.10	FTIR transmission spectra of bioactive glass sample TZ4 before and after SBF treatment.	188